Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in BrazilGlobeNewsWire • 10/16/23
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic DermatitisBusiness Wire • 10/13/23
Data From Incyte's Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)Business Wire • 10/13/23
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo PatientsBusiness Wire • 10/11/23
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of ClarityBusiness Wire • 10/11/23
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental VitiligoBusiness Wire • 10/11/23
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) CongressBusiness Wire • 09/29/23
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi RivalInvestors Business Daily • 09/18/23
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 08/01/23
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell CarcinomaBusiness Wire • 07/31/23
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host DiseasePRNewsWire • 07/24/23